Subramanian Sivarajan, MD
Nephrology · Palo Alto
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: 052793 · Mills-Peninsula Medical Center · Sequoia Hospital. That is not proof they admit you there this week.
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Sivarajan’s office at (415) 600-1020 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence C53314 · Current
Licensed to practise in California · since 2008 · expires 2028-06-30 · University of Madras, Thanjavur Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sequoia HospitalRedwood City, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Death rate among surgical inpatients with serious treatable complications: 104.12 (51.8 to 156.44) · 56 cases, Jul 2022 – Jun 2024Better than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sequoia Hospital
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 3 better, 6 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 104.12 (51.8 to 156.44) · 56 cases | Better | Jul 2022 – Jun 2024 |
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.95 (0 to 1.98) · 472 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.91 (0.58 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.8 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.1 · 258 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.5 · 171 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 81 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,231 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.23 (0.01 to 0.44) · 3,018 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.44) · 3,164 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.59 (0.47 to 4.71) · 1,402 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.47 (0.04 to 2.9) · 926 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.68 (0.21 to 3.16) · 1,310 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.54 (4.42 to 14.67) · 978 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.98 (1.61 to 8.36) · 924 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.19) · 192 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.57 (0 to 1.43) · 2,501 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.5 · 332 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.702 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.853 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 67 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 295 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -27.1 · 76 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.3 · 304 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.6 · 178 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.3 · 180 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 305 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 41 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 29 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.1 (9.7 to 17.7) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 713 cases | No different | Jan 2024 – Dec 2024 |
What patients said (631 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 82% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 81% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 77% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$150,709
Medicare paid this office $150,709 for 543 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 306 | $45,545 | $108 |
| Long return visit (40+ min) | 140 | $29,049 | $156 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31 | $26,807 | None |
| New patient visit (60+ min) | 135 | $25,449 | $189 |
| New patient visit (45+ min) | 33 | $5,011 | $152 |
See all 9 services
| Return visit (30+ min) | 306 | $45,545 | $108 |
| Long return visit (40+ min) | 140 | $29,049 | $156 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 31 | $26,807 | None |
| New patient visit (60+ min) | 135 | $25,449 | $189 |
| New patient visit (45+ min) | 33 | $5,011 | $152 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $4,854 | $103 |
| Short return visit (20+ min) | 52 | $4,720 | $84 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,621 | $65 |
| Injection of drug or substance under skin or into muscle | 30 | $1,469 | $14 |
Who their Medicare patients are
543 Original Medicare patients in 2024. Average age 79 · 85 and older 28% · Women 45% · Also on Medicaid 9% · Health risk score 1.87. At or below the middle of the specialty; the typical nephrology clinician is at 4.01.
Conditions among them: High blood pressure 75% · Chronic kidney disease 75% · Diabetes 44% · Coronary heart disease 39% · Atrial fibrillation 30% · Heart failure 27% · Cancer 18% · Depression 15% · COPD 10% · Dementia 9% · Stroke 6%.
The office billed $681,756, Medicare allowed $205,598 and paid $150,709; for 12,812 services of 17 kinds; $27,053 of it was for drugs given in the office and $123,656 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 543 | 12,812 | 79 | 1.87 | $681,756 | $150,709 |
| 2023 | 501 | 7,161 | 79 | 1.68 | $566,335 | $145,734 |
| 2022 | 538 | 10,968 | 78 | 1.73 | $640,589 | $162,621 |
| 2021 | 477 | 8,698 | 78 | 1.86 | $520,570 | $136,234 |
| 2020 | 367 | 7,697 | 77 | 2.12 | $507,016 | $122,291 |
| 2019 | 405 | 8,854 | 78 | 2.21 | $528,100 | $142,056 |
| 2018 | 369 | 9,731 | 77 | 2.28 | $425,374 | $114,731 |
| 2017 | 313 | 6,018 | 77 | 2.25 | $288,854 | $86,056 |
| 2016 | 801 | 4,618 | 73 | 3.34 | $368,809 | $151,052 |
| 2015 | 757 | 4,101 | 72 | 4.13 | $392,124 | $160,314 |
| 2014 | 803 | 5,309 | 72 | 3.77 | $457,452 | $188,095 |
| 2013 | 794 | 4,436 | 72 | 4.07 | $521,709 | $205,373 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Long return visit (40+ min) | 200 | $45,056 | $162 |
| Return visit (30+ min) | 260 | $40,073 | $110 |
| New patient visit (60+ min) | 149 | $28,669 | $192 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22 | $14,197 | None |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,426 | $105 |
| New patient visit (45+ min) | 12 | $1,760 | $147 |
| Injection of drug or substance under skin or into muscle | 21 | $777 | $14 |
2022: 9 services
| Return visit (30+ min) | 301 | $55,547 | $116 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 29 | $24,633 | None |
| New patient visit (60+ min) | 104 | $21,347 | $205 |
| New patient visit (45+ min) | 112 | $16,298 | $146 |
| Long return visit (40+ min) | 71 | $14,190 | $169 |
| Short return visit (20+ min) | 80 | $6,137 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $3,244 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $1,578 | $63 |
| Injection of drug or substance under skin or into muscle | 29 | $1,190 | $15 |
2021: 9 services
| Return visit (30+ min) | 238 | $42,954 | $115 |
| New patient visit (45+ min) | 186 | $28,871 | $155 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $19,488 | None |
| Short return visit (20+ min) | 139 | $15,528 | $84 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 12 | $5,450 | $260 |
| New patient visit (60+ min) | 19 | $3,504 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,750 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,509 | $94 |
| Injection of drug or substance under skin or into muscle | 23 | $1,127 | $14 |
2020: 13 services
| Return visit (30+ min) | 201 | $28,205 | $90 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 28 | $19,574 | None |
| New patient visit (60+ min) | 87 | $15,838 | $182 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 12 | $9,185 | $224 |
| Dialysis services, 1 physician visit per month (20 years or older) | 13 | $8,412 | $175 |
| Long return visit (40+ min) | 49 | $8,175 | $118 |
| Telephone medical discussion with physician, 11-20 minutes | 48 | $4,288 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $3,570 | $96 |
| New patient visit (45+ min) | 18 | $2,636 | $146 |
| Short return visit (20+ min) | 30 | $2,077 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $1,936 | $60 |
| Injection of drug or substance under skin or into muscle | 29 | $1,041 | $13 |
| Hemodialysis procedure with physician evaluation | 13 | $1,008 | $63 |
2019: 11 services
| Return visit (30+ min) | 256 | $45,311 | $95 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 30 | $22,427 | None |
| New patient visit (60+ min) | 105 | $18,733 | $178 |
| Long return visit (40+ min) | 92 | $16,890 | $133 |
| Dialysis services, 1 physician visit per month (20 years or older) | 11 | $5,703 | $163 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 12 | $5,508 | $220 |
| New patient visit (45+ min) | 31 | $4,163 | $134 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $4,039 | $92 |
| Short return visit (20+ min) | 40 | $2,272 | $57 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,121 | $62 |
| Injection of drug or substance under skin or into muscle | 29 | $1,253 | $16 |
2018: 10 services
| Return visit (30+ min) | 242 | $44,593 | $92 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $24,607 | None |
| New patient visit (45+ min) | 82 | $11,289 | $138 |
| New patient visit (60+ min) | 54 | $9,996 | $185 |
| Long return visit (40+ min) | 20 | $2,997 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,808 | $62 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $1,952 | $93 |
| Hemodialysis procedure with physician evaluation | 17 | $1,937 | $65 |
| Short return visit (20+ min) | 29 | $1,845 | $60 |
| Injection of drug or substance under skin or into muscle | 22 | $1,625 | $20 |
2017: 10 services
| Return visit (30+ min) | 155 | $26,952 | $100 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 17 | $16,132 | None |
| New patient visit (45+ min) | 101 | $14,568 | $144 |
| Short return visit (20+ min) | 95 | $7,410 | $66 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,815 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 18 | $2,519 | $93 |
| Long return visit (40+ min) | 14 | $2,028 | $135 |
| New patient visit (30+ min) | 15 | $1,227 | $82 |
| Injection of drug or substance under skin or into muscle | 18 | $1,214 | $26 |
| Automated urinalysis test | 20 | $60 | $3 |
2016: 16 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 32 | $44,329 | $213 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 255 | $25,272 | $54 |
| Short return visit (20+ min) | 275 | $20,852 | $49 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22 | $9,069 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 79 | $7,973 | $101 |
| New patient visit (45+ min) | 65 | $7,306 | $112 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 72 | $7,011 | $78 |
| Hemodialysis procedure with physician evaluation | 78 | $6,413 | $54 |
| Return visit (30+ min) | 41 | $3,192 | $73 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 15 | $3,043 | $179 |
| New patient visit (30+ min) | 36 | $2,705 | $75 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 32 | $2,406 | $75 |
| Short return visit | 50 | $1,563 | $31 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 24 | $852 | $29 |
| Injection of drug or substance under skin or into muscle | 23 | $775 | $18 |
| Manual urinalysis test with examination using microscope, non-automated | 11 | $47 | $4 |
2015: 15 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 28 | $49,998 | $219 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 331 | $32,291 | $56 |
| Short return visit (20+ min) | 206 | $14,778 | $47 |
| Hemodialysis procedure with physician evaluation | 116 | $12,608 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 82 | $8,708 | $106 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $8,471 | $81 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 16 | $6,854 | None |
| New patient visit (45+ min) | 32 | $3,814 | $119 |
| Return visit (30+ min) | 41 | $3,581 | $80 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 13 | $2,614 | $187 |
| New patient visit (30+ min) | 33 | $2,293 | $69 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 25 | $1,964 | $79 |
| Short return visit | 34 | $993 | $29 |
| Injection of drug or substance under skin or into muscle | 16 | $751 | $19 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $699 | $30 |
2014: 14 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 43 | $64,743 | $222 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 321 | $29,764 | $56 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 120 | $14,831 | $81 |
| Hemodialysis procedure with physician evaluation | 133 | $12,338 | $57 |
| Return visit (30+ min) | 138 | $11,790 | $69 |
| Short return visit (20+ min) | 158 | $9,639 | $50 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 24 | $8,932 | None |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 63 | $6,672 | $106 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $5,089 | $159 |
| New patient visit (45+ min) | 29 | $3,587 | $124 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 14 | $2,809 | $187 |
| Injection of drug or substance under skin or into muscle | 25 | $1,046 | $18 |
| Short return visit | 25 | $762 | $29 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 18 | $641 | $31 |
2013: 19 services
| Dialysis services, 4 or more physician visits per month (20 years or older) | 45 | $72,182 | $215 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 263 | $27,360 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 147 | $19,349 | $79 |
| Return visit (30+ min) | 188 | $18,765 | $70 |
| Hemodialysis procedure with physician evaluation | 131 | $17,859 | $56 |
| Home dialysis services per month (20 years or older) | 12 | $10,951 | $186 |
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 21 | $5,432 | None |
| Short return visit (20+ min) | 103 | $5,364 | $47 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $5,270 | $155 |
| New patient visit (45+ min) | 46 | $5,216 | $113 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 48 | $5,065 | $106 |
| New patient visit (60+ min) | 17 | $2,436 | $143 |
| Long return visit (40+ min) | 11 | $1,318 | $110 |
| Dialysis services, per day, less than full month service (20 years or older) | 15 | $1,117 | $6 |
| New patient visit (30+ min) | 12 | $944 | $79 |
| Injection of drug or substance under skin or into muscle | 21 | $791 | $20 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 21 | $776 | $30 |
| Short return visit | 23 | $662 | $28 |
| Manual urinalysis test with examination using microscope, non-automated | 32 | $137 | $4 |
Drugs they prescribed that Part D paid
$473,657
Pharmacies billed $473,657 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 1,362) in 2024. At or below the middle of the specialty; the typical nephrology clinician is at 0%.
1,090 generic and 272 brand-name prescriptions · $473,657 in drug cost · 12 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Filspari | 12 | $127,444 | $10,620 |
| Farxiga | 96 | $125,683 | $1,309 |
| Jardiance | 70 | $91,486 | $1,307 |
| Lokelma | 44 | $51,734 | $1,176 |
| Calcitriol | 229 | $2,761 | $12 |
See all 21 drugs
| Filspari | 12 | $127,444 | $10,620 |
| Farxiga | 96 | $125,683 | $1,309 |
| Jardiance | 70 | $91,486 | $1,307 |
| Lokelma | 44 | $51,734 | $1,176 |
| Calcitriol | 229 | $2,761 | $12 |
| Sevelamer Carbonate | 13 | $2,381 | $183 |
| Losartan | 222 | $2,227 | $10 |
| Potassium Citrate Er | 12 | $1,462 | $122 |
| Tacrolimus | 20 | $1,324 | $66 |
| Mycophenolate Mofetil | 18 | $819 | $46 |
| Furosemide | 122 | $649 | $5 |
| Amlodipine Besylate | 76 | $580 | $8 |
| Nifedipine Er | 12 | $505 | $42 |
| Allopurinol | 38 | $373 | $10 |
| Prednisone | 37 | $312 | $8 |
| Spironolactone | 25 | $264 | $11 |
| Carvedilol | 11 | $243 | $22 |
| Clonidine | 20 | $240 | $12 |
| Atorvastatin | 30 | $227 | $8 |
| Lisinopril | 20 | $153 | $8 |
| Tamsulosin | 12 | $87 | $7 |
Year by year
| 2024 | 1,362 | 272 | 0% (0) | 20% | $473,657 |
| 2023 | 1,356 | 249 | 0% (0) | 19% | $312,271 |
| 2022 | 1,116 | 210 | None | 22% | $210,483 |
| 2021 | 934 | 179 | None | 22% | $115,827 |
| 2020 | 802 | 133 | None | 19% | $74,269 |
| 2019 | 820 | 144 | None | 14% | $58,065 |
| 2018 | 920 | 149 | None | 16% | $88,220 |
| 2017 | 1,095 | 237 | None | 20% | $107,629 |
| 2016 | 1,434 | 212 | 2% (21) | None | $95,188 |
| 2015 | 1,105 | 160 | 1% (13) | None | $92,768 |
| 2014 | 1,095 | 159 | None | 19% | $80,937 |
| 2013 | 1,410 | 181 | None | None | $143,693 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Farxiga | 94 | $98,668 | $1,050 |
| Jardiance | 73 | $86,655 | $1,187 |
| Lokelma | 42 | $50,315 | $1,198 |
| Veltassa | 20 | $29,573 | $1,479 |
| Sevelamer Carbonate | 31 | $5,304 | $171 |
| Tacrolimus | 22 | $3,605 | $164 |
| Calcitriol | 226 | $2,737 | $12 |
| Losartan | 164 | $2,670 | $16 |
| Mycophenolate Mofetil | 16 | $849 | $53 |
| Nifedipine Er | 13 | $821 | $63 |
| Allopurinol | 41 | $769 | $19 |
| Furosemide | 122 | $737 | $6 |
| Amlodipine Besylate | 88 | $588 | $7 |
| Potassium Chloride | 15 | $360 | $24 |
| Carvedilol | 24 | $302 | $13 |
| Prednisone | 40 | $292 | $7 |
| Gabapentin | 17 | $224 | $13 |
| Metoprolol | 11 | $206 | $19 |
| Tamsulosin | 22 | $177 | $8 |
| Spironolactone | 17 | $174 | $10 |
| Clonidine | 13 | $146 | $11 |
| Lisinopril | 17 | $97 | $6 |
| Atorvastatin | 33 | $93 | $3 |
2022: 20 drugs
| Jardiance | 76 | $74,170 | $976 |
| Farxiga | 78 | $59,313 | $760 |
| Veltassa | 21 | $25,045 | $1,193 |
| Sevelamer Carbonate | 22 | $3,125 | $142 |
| Tacrolimus | 18 | $3,045 | $169 |
| Calcitriol | 177 | $2,134 | $12 |
| Losartan | 144 | $1,985 | $14 |
| Mycophenolate Mofetil | 14 | $1,530 | $109 |
| Allopurinol | 51 | $855 | $17 |
| Bumetanide | 13 | $836 | $64 |
| Nifedipine Er | 12 | $758 | $63 |
| Amlodipine Besylate | 55 | $637 | $12 |
| Furosemide | 89 | $464 | $5 |
| Carvedilol | 20 | $306 | $15 |
| Prednisone | 29 | $277 | $10 |
| Gabapentin | 18 | $204 | $11 |
| Metoprolol | 12 | $197 | $16 |
| Atorvastatin | 19 | $176 | $9 |
| Clonidine | 16 | $155 | $10 |
| Lisinopril | 20 | $72 | $4 |
2021: 15 drugs
| Jardiance | 49 | $40,133 | $819 |
| Veltassa | 12 | $9,785 | $815 |
| Sevelamer Carbonate | 20 | $2,139 | $107 |
| Losartan | 116 | $1,646 | $14 |
| Prosol | 47 | $1,550 | $33 |
| Calcitriol | 108 | $1,434 | $13 |
| Amlodipine Besylate | 58 | $809 | $14 |
| Allopurinol | 48 | $774 | $16 |
| Furosemide | 92 | $564 | $6 |
| Lisinopril | 43 | $450 | $10 |
| Carvedilol | 13 | $315 | $24 |
| Tamsulosin | 12 | $179 | $15 |
| Atorvastatin | 22 | $166 | $8 |
| Metoprolol | 11 | $149 | $14 |
| Prednisone | 11 | $135 | $12 |
2020: 14 drugs
| Renvela | 16 | $15,478 | $967 |
| Sevelamer Carbonate | 33 | $5,494 | $166 |
| Losartan | 86 | $1,087 | $13 |
| Allopurinol | 69 | $829 | $12 |
| Furosemide | 103 | $675 | $7 |
| Amlodipine Besylate | 47 | $624 | $13 |
| Calcitriol | 51 | $521 | $10 |
| Pravastatin | 17 | $462 | $27 |
| Lisinopril | 53 | $447 | $8 |
| Atorvastatin | 23 | $330 | $14 |
| Carvedilol | 15 | $303 | $20 |
| Tamsulosin | 20 | $287 | $14 |
| Clonidine | 14 | $180 | $13 |
| Prednisone | 11 | $107 | $10 |
2019: 18 drugs
| Renvela | 19 | $13,844 | $729 |
| Sevelamer Carbonate | 30 | $10,911 | $364 |
| Calcitriol | 119 | $1,804 | $15 |
| Allopurinol | 71 | $1,069 | $15 |
| Losartan | 71 | $806 | $11 |
| Amlodipine Besylate | 53 | $582 | $11 |
| Pravastatin | 28 | $564 | $20 |
| Furosemide | 80 | $448 | $6 |
| Labetalol | 11 | $423 | $38 |
| Lidocaine-Prilocaine | 13 | $409 | $31 |
| Atorvastatin | 26 | $406 | $16 |
| Tamsulosin | 11 | $381 | $35 |
| Lisinopril | 25 | $153 | $6 |
| Simvastatin | 11 | $142 | $13 |
| Prednisone | 12 | $105 | $9 |
| Clonidine | 14 | $100 | $7 |
| Hydrochlorothiazide | 11 | $70 | $6 |
| Zolpidem | 13 | $49 | $4 |
2018: 21 drugs
| Renvela | 24 | $32,084 | $1,337 |
| Sevelamer Carbonate | 17 | $6,209 | $365 |
| Calcitriol | 135 | $2,460 | $18 |
| Prosol | 15 | $2,042 | $136 |
| Allopurinol | 60 | $803 | $13 |
| Losartan | 83 | $675 | $8 |
| Pravastatin | 28 | $610 | $22 |
| Amlodipine Besylate | 55 | $601 | $11 |
| Atorvastatin | 27 | $594 | $22 |
| Lidocaine-Prilocaine | 12 | $499 | $42 |
| Furosemide | 71 | $352 | $5 |
| Prednisone | 35 | $320 | $9 |
| Hydralazine | 21 | $241 | $11 |
| Minoxidil | 15 | $228 | $15 |
| Lisinopril | 30 | $186 | $6 |
| Carvedilol | 12 | $179 | $15 |
| Simvastatin | 15 | $158 | $11 |
| Metoprolol | 16 | $106 | $7 |
| Zolpidem | 13 | $89 | $7 |
| Hydrochlorothiazide | 11 | $51 | $5 |
| Sulfamethoxazole-Trimethoprim | 12 | $48 | $4 |
2017: 27 drugs
| Renvela | 27 | $32,034 | $1,186 |
| Sensipar | 20 | $28,223 | $1,411 |
| Paricalcitol | 32 | $3,809 | $119 |
| Calcium Acetate | 19 | $2,230 | $117 |
| Calcitriol | 105 | $1,976 | $19 |
| Potassium Chloride | 32 | $1,800 | $56 |
| Valsartan | 21 | $1,566 | $75 |
| Allopurinol | 101 | $1,052 | $10 |
| Labetalol | 15 | $1,022 | $68 |
| Lidocaine-Prilocaine | 12 | $667 | $56 |
| Pravastatin | 19 | $501 | $26 |
| Furosemide | 93 | $446 | $5 |
| Amlodipine Besylate | 64 | $445 | $7 |
| Atorvastatin | 21 | $342 | $16 |
| Losartan | 36 | $273 | $8 |
| Hydralazine | 17 | $243 | $14 |
| Lisinopril | 53 | $243 | $5 |
| Carvedilol | 24 | $178 | $7 |
| Clonidine | 21 | $177 | $8 |
| Metoprolol | 18 | $170 | $9 |
| Levothyroxine | 12 | $139 | $12 |
| Prednisone | 24 | $137 | $6 |
| Simvastatin | 16 | $118 | $7 |
| Hydrochlorothiazide | 16 | $97 | $6 |
| Zolpidem | 12 | $73 | $6 |
| Losartan-Hydrochlorothiazide | 13 | $50 | $4 |
| Lovastatin | 11 | $22 | $2 |
2016: 31 drugs
| Sensipar | 24 | $31,141 | $1,298 |
| Renvela | 30 | $21,000 | $700 |
| Paricalcitol | 76 | $8,832 | $116 |
| Uloric | 14 | $3,913 | $280 |
| Calcium Acetate | 36 | $3,084 | $86 |
| Allopurinol | 134 | $1,254 | $9 |
| Potassium Chloride | 33 | $1,238 | $38 |
| Calcitriol | 88 | $1,234 | $14 |
| Furosemide | 162 | $818 | $5 |
| Lisinopril | 172 | $801 | $5 |
| Valsartan | 26 | $664 | $26 |
| Labetalol | 14 | $629 | $45 |
| Doxazosin Mesylate | 12 | $473 | $39 |
| Tolterodine Tartrate Er | 12 | $436 | $36 |
| Clonidine | 48 | $387 | $8 |
| Losartan | 44 | $374 | $9 |
| Azathioprine | 12 | $361 | $30 |
| Hydralazine | 32 | $345 | $11 |
| Omeprazole | 24 | $224 | $9 |
| Amlodipine Besylate | 32 | $219 | $7 |
| Metoprolol | 22 | $214 | $10 |
| Tramadol | 12 | $196 | $16 |
| Glyburide | 13 | $150 | $12 |
| Atorvastatin | 18 | $136 | $8 |
| Klor-Con M20 | 13 | $134 | $10 |
| Levothyroxine | 12 | $129 | $11 |
| Hydrochlorothiazide | 21 | $127 | $6 |
| Prednisone | 14 | $66 | $5 |
| Carvedilol | 14 | $45 | $3 |
| Alprazolam | 15 | $38 | $3 |
| Atenolol | 11 | $16 | $1 |
2015: 26 drugs
| Renvela | 40 | $38,536 | $963 |
| Sensipar | 18 | $20,132 | $1,118 |
| Paricalcitol | 114 | $12,982 | $114 |
| Uloric | 12 | $3,052 | $254 |
| Calcium Acetate | 31 | $2,590 | $84 |
| Allopurinol | 97 | $1,181 | $12 |
| Calcitriol | 72 | $1,111 | $15 |
| Potassium Chloride | 18 | $824 | $46 |
| Azathioprine | 11 | $701 | $64 |
| Furosemide | 125 | $689 | $6 |
| Labetalol | 17 | $501 | $29 |
| Hydralazine | 33 | $415 | $13 |
| Lisinopril | 103 | $392 | $4 |
| Omeprazole | 25 | $278 | $11 |
| Metoprolol | 17 | $256 | $15 |
| Doxazosin Mesylate | 11 | $226 | $21 |
| Clonidine | 20 | $211 | $11 |
| Glyburide | 25 | $210 | $8 |
| Amlodipine Besylate | 18 | $195 | $11 |
| Metoclopramide | 15 | $144 | $10 |
| Hydrochlorothiazide | 24 | $137 | $6 |
| Carvedilol | 16 | $100 | $6 |
| Alprazolam | 24 | $80 | $3 |
| Ciprofloxacin | 14 | $66 | $5 |
| Prednisone | 12 | $47 | $4 |
| Zolpidem | 13 | $21 | $2 |
2014: 31 drugs
| Renvela | 17 | $25,109 | $1,477 |
| Paricalcitol | 113 | $16,846 | $149 |
| Calcium Acetate | 33 | $3,409 | $103 |
| Colcrys | 11 | $3,054 | $278 |
| Uloric | 12 | $2,693 | $224 |
| Crestor | 11 | $2,121 | $193 |
| Calcitriol | 77 | $1,538 | $20 |
| Doxazosin Mesylate | 25 | $637 | $25 |
| Allopurinol | 90 | $577 | $6 |
| Labetalol | 19 | $574 | $30 |
| Hydralazine | 28 | $497 | $18 |
| Furosemide | 108 | $463 | $4 |
| Amlodipine Besylate | 55 | $385 | $7 |
| Losartan | 16 | $360 | $23 |
| Clonidine | 37 | $316 | $9 |
| Lisinopril | 70 | $315 | $5 |
| Atorvastatin | 18 | $279 | $16 |
| Metolazone | 14 | $270 | $19 |
| Omeprazole | 15 | $259 | $17 |
| Lovastatin | 12 | $241 | $20 |
| Potassium Chloride | 13 | $208 | $16 |
| Simvastatin | 14 | $146 | $10 |
| Zolpidem | 12 | $139 | $12 |
| Glyburide | 17 | $115 | $7 |
| Gentamicin Sulfate | 11 | $106 | $10 |
| Famotidine | 13 | $104 | $8 |
| Prednisone | 15 | $103 | $7 |
| Glyburide Micronized | 11 | $97 | $9 |
| Losartan-Hydrochlorothiazide | 12 | $87 | $7 |
| Metoprolol | 12 | $53 | $4 |
| Alprazolam | 13 | $41 | $3 |
2013: 42 drugs
| Renvela | 56 | $53,686 | $959 |
| Sensipar | 31 | $22,870 | $738 |
| Zemplar | 87 | $18,639 | $214 |
| Colcrys | 24 | $5,263 | $219 |
| Micardis | 21 | $4,472 | $213 |
| Calcium Acetate | 12 | $2,992 | $249 |
| Paricalcitol | 13 | $2,523 | $194 |
| Calcitriol | 88 | $2,012 | $23 |
| Nitrofurantoin Mono-Macro | 11 | $857 | $78 |
| Clonidine | 88 | $697 | $8 |
| Labetalol | 15 | $685 | $46 |
| Allopurinol | 97 | $570 | $6 |
| Losartan | 29 | $568 | $20 |
| Amlodipine Besylate | 72 | $515 | $7 |
| Furosemide | 102 | $486 | $5 |
| Lidocaine-Prilocaine | 11 | $480 | $44 |
| Hydralazine | 19 | $428 | $23 |
| Metoprolol | 19 | $423 | $22 |
| Lisinopril | 50 | $318 | $6 |
| Atorvastatin | 14 | $315 | $23 |
| Doxazosin Mesylate | 12 | $307 | $26 |
| Simvastatin | 22 | $265 | $12 |
| Metolazone | 15 | $246 | $16 |
| Ranitidine | 23 | $225 | $10 |
| Montelukast | 11 | $209 | $19 |
| Levothyroxine | 20 | $196 | $10 |
| Omeprazole | 13 | $125 | $10 |
| Glyburide Micronized | 18 | $115 | $6 |
| Lovastatin | 13 | $115 | $9 |
| Azithromycin | 11 | $111 | $10 |
| Famotidine | 15 | $103 | $7 |
| Sertraline | 13 | $99 | $8 |
| Losartan-Hydrochlorothiazide | 13 | $90 | $7 |
| Glyburide | 12 | $90 | $8 |
| Gentamicin Sulfate | 11 | $82 | $7 |
| Carvedilol | 11 | $78 | $7 |
| Ciprofloxacin | 12 | $77 | $6 |
| Alprazolam | 16 | $74 | $5 |
| Meloxicam | 12 | $73 | $6 |
| Hydrochlorothiazide | 16 | $66 | $4 |
| Prednisone | 16 | $57 | $4 |
| Zolpidem | 12 | $56 | $5 |
Money from drug and device companies
$997 in 2025
| 2025 | 8 | 21 | None | $997 |
| 2024 | 8 | 20 | None | $822 |
| 2023 | 11 | 29 | None | $616 |
| 2022 | 8 | 37 | None | $717 |
| 2021 | 6 | 25 | None | $541 |
| 2020 | 4 | 11 | None | $313 |
| 2019 | 7 | 46 | None | $1,557 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Otsuka America Pharmaceutical | Jynarque | $419 | 3 payments
|
| Travere Therapeutics | Filspari | $191 | 6 payments
|
| Calliditas Therapeutics US | Tarpeyo | $137 | 2 payments
|
| Novartis Pharmaceuticals | Fabhalta | $118 | 5 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $57 | 2 payments
|
| Veloxis Pharmaceuticals | Envarsus | $32 | 1 payment
|
See all 21 published payments
| Otsuka America Pharmaceutical | Meals · 2025-11-07 | None | $150 |
| Otsuka America Pharmaceutical | Meals · 2025-11-06 | None | $147 |
| Novartis Pharmaceuticals | Meals · 2025-09-21 | Fabhalta | $19 |
| Novartis Pharmaceuticals | Meals · 2025-09-21 | Fabhalta | $19 |
| Calliditas Therapeutics US | Meals · 2025-08-25 | Tarpeyo | $12 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-07-14 | Jardiance | $29 |
| Alexion Pharmaceuticals | Meals · 2025-07-08 | Ultomiris | $22 |
| Veloxis Pharmaceuticals | Meals · 2025-05-19 | Envarsus | $32 |
| Travere Therapeutics | Meals · 2025-05-14 | Filspari | $125 |
| Novartis Pharmaceuticals | Meals · 2025-05-05 | Fabhalta | $26 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-24 | Farxiga | $20 |
| Otsuka America Pharmaceutical | Meals · 2025-03-20 | Jynarque | $122 |
| Travere Therapeutics | Meals · 2025-03-20 | None | $9 |
| Travere Therapeutics | Meals · 2025-03-18 | None | $5 |
| Travere Therapeutics | Meals · 2025-03-18 | None | $12 |
| Travere Therapeutics | Meals · 2025-03-04 | None | $19 |
| Calliditas Therapeutics US | Meals · 2025-03-03 | Tarpeyo | $125 |
| Novartis Pharmaceuticals | Meals · 2025-02-27 | Fabhalta | $29 |
| Novartis Pharmaceuticals | Meals · 2025-02-27 | Fabhalta | $24 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-10 | Jardiance | $28 |
| Travere Therapeutics | Meals · 2025-02-04 | None | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $822
| Travere Therapeutics | None | $253 | 3 payments
|
| Amgen | Tavneos | $247 | 6 payments
|
| Ardelyx | Xphozah 30 Mg | $194 | 5 payments
|
| Calliditas Therapeutics US | Tarpeyo | $46 | 2 payments
|
| Kyowa Kirin | Crysvita | $24 | 1 payment
|
| Fresenius USA Marketing | Velphoro | $22 | 1 payment
|
| OPKO Pharmaceuticals | Rayaldee | $19 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $16 | 1 payment
|
2023: $616
| Amgen | Aranesp | $102 | 4 payments
|
| Travere Therapeutics | None | $90 | 6 payments
|
| GlaxoSmithKline | Benlysta | $73 | 3 payments
|
| Vifor Pharma | Veltassa | $69 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $60 | 3 payments
|
| Alexion Pharmaceuticals | Ultomiris | $53 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $42 | 2 payments
|
| ANI Pharmaceuticals | Purified Cortrophin Gel | $38 | 2 payments
|
| Aurinia Pharma U.S. | Lupkynis | $35 | 2 payments
|
| Novartis Pharmaceuticals | None | $29 | 1 payment
|
| Ardelyx | Ibsrela | $27 | 1 payment
|
2022: $717
| Amgen | Tavneos | $253 | 13 payments
|
| Vifor Pharma | Veltassa | $211 | 11 payments
|
| Fresenius USA Marketing | Velphoro | $115 | 6 payments
|
| GlaxoSmithKline | Benlysta | $57 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $37 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $18 | 1 payment
|
| Exeltis USA | Purified Cortrophin Gel | $13 | 1 payment
|
| Otsuka America Pharmaceutical | Jynarque | $13 | 1 payment
|
2021: $541
| Vifor Pharma | Veltassa | $165 | 9 payments
|
| Fresenius USA Marketing | Velphoro | $156 | 9 payments
|
| Alexion Pharmaceuticals | None | $116 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $70 | 4 payments
|
| Amgen | Parsabiv | $19 | 1 payment
|
| GlaxoSmithKline | Benlysta | $16 | 1 payment
|
2020: $313
| AstraZeneca Pharmaceuticals LP | Lokelma | $236 | 7 payments
|
| Otsuka America Pharmaceutical | Jynarque | $37 | 2 payments
|
| Alexion Pharmaceuticals | Ultomiris | $21 | 1 payment
|
| Amgen | Parsabiv | $18 | 1 payment
|
2019: $1,557
| Relypsa | Veltassa | $461 | 20 payments
|
| AstraZeneca Pharmaceuticals LP | Lokelma | $309 | 6 payments
|
| Bard Peripheral Vascular | None | $285 | 2 payments
|
| Alexion Pharmaceuticals | None | $249 | 2 payments
|
| Otsuka America Pharmaceutical | Jynarque | $151 | 11 payments
|
| Amgen | Aranesp | $61 | 3 payments
|
| Fresenius USA Marketing | Velphoro | $41 | 2 payments
|
Professional record
- NPI
- 1154310951
- Licence
- CA C53314, MO 103776California C53314: Current · expires 2028-06-30
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- KS 100150360B, MO 206687709
- Taxonomy
- Federal specialty code 207RN0300X (207RN0300X)
- Mailing address
- 795 El Camino Real Fl 2, Palo Alto, CA, 94301
- NPI first listed
- 2005-10-14
- NPI last updated
- 2024-04-23
- NPI record certified
- 2024-04-23
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 325 Distel Cir, Los Altos, CA, 94022